论文部分内容阅读
据2005年美国临床肿瘤学会年会报道,在晚期非小细胞肺癌(NSCLC)患者的标准化疗中,加用血管生成素抑制剂bevacizumab(Avastin)药物能使NSCLC患者的两年生存率提高至23%。美国田纳西州Vanderbilt大学医学中心的AlanB.Sandler博士指出,在该药的III期临床试验中,结合靶向治疗的标准化学疗法可改善NSCLC患者的生存率,这是近十年来取得的初步进展。试验中434例未经治疗的IIIb或IV期NSCLC患者被分为bevacizumab联合标准化疗试验组,即接受PCB疗法;444例仅采用标准化疗的患者被划入对照组。试验结果显示PCB组患者的平均生存期为
According to the 2005 annual meeting of the American Society of Clinical Oncology, the addition of bevacizumab (Avastin) to the standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) increased the two-year survival rate of NSCLC patients to 23 %. AlanB.Sandler, Vanderbilt University Medical Center, Tennessee, USA, points out that the standard chemotherapy combined with targeted therapy can improve the survival rate of patients with NSCLC in phase III of the drug, which is the first progress made in the past ten years. In the trial, 434 untreated patients with stage IIIb or IV NSCLC were randomized into bevacizumab plus a standard chemotherapy trial to receive PCB therapy; 444 patients who received standard chemotherapy alone were enrolled in the control arm. The results showed that the average survival of patients in the PCB group was